Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults;Chimiothérapie néoadjuvante dans les astrocytomes fibrillaires de grade II symptomatiques non opérables de l'adulte

Revue Neurologique

Volumn 160, Issue 5 I, 2004, Pages 533-537

  Lebrun, C ^a   Fontaine, D ^a   Vandenbos, F ^a   Chanalet, S ^a   Bourg, V ^a   Frenay M ^b   Alchaar, H ^c   Bleuse, A ^c   Bondiau, P Y ^c   Brunetto, J L ^c   Chatel, M ^c   Courdi, A ^c   Darcourt, J ^c   Fauchon, F ^c   Guibert, F ^c   Grellier, P ^c   Lanteri Minet, M ^c   Lonjon, M ^c   Michiels, J F ^c   Paquis, P ^c   Paquis, V ^c   Ramaioli, A ^c   Rasendrarijao, D ^c   more..

^a PASTEUR HOSPITAL   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c Hôpital Pasteur ^*

Author keywords

Brain tumors; Chemotherapy; Low grade astrocytomas

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CASE REPORT; CLINICAL ARTICLE; EPILEPSY; FEMALE; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; SEIZURE; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 2942722680     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(04)70982-0     Document Type: Article

References (33)

1. BEHIN A, DELATTRE JY. (2002). Neurologic sequelae of radiotherapy on the nervous system. In Cancer neurology in clinical practice. Humana Press Inc (Totowa). Schiff and Wen eds: pp173-191.
2. BOURG V, LEBRUN C, CHICHMANIAN RM, THOMAS P, FRENAY M. (2001). Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol, 12: 217-219.
3. BROWN PD, BUCKNER JC, O'FALLON JR, et al. (2003a). Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by Folstein mini-mental state examination. J Clin Oncol, 13: 2519-2524.
4. BROWN PD, BUCKNER JC, UHM JH, SHAW EG. (2003b). The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro-oncol, 5: 161-167.
5. BUCKNER JC, GESME D, O'FALLON JR, et al. (2003). Phase II trial of procarbazine, lomustine and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol, 21: 251-255.
6. CAIRNCROSS JG, UEKI K, ZLATESCU MC, et al. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligoendrogliomas. J Nat C Inst, 90: 1473-1479.
7. CAIRNCROSS JG. (2000). Understanding low-grade glioma. A decade of progress. Neurology, 54: 1402-1403.
8. DE ANGELIS (2001). Brain tumors. New Eng J Med, 344: 114-123.
9. DUFFAU H, CAPELLE L, DENVIL D, et al. (2003). Usefullness of intraoperative functionnal subcortical maping during surgery for low grade gliomas located within eloquent brain region: functionnal results in a consecutive serie of 103 patients. J Neurosurg, 98: 764-778.
10. EAGAN RT, DINAPOLI RP, HERMAN RC, et al. (1982). Combinaton carmustine (BCNU) and dihydrogalactilol in the treatment of primary brain tumors recurring after irradiation. Cancer treat reports, 66: 1647-1649.
11. EYRE HJ, ELTRINGHAM JR, CROWLEY J, MORANTZ RA. (1993). A randomized trial of radiotherapy vs RT+CCNU for incompletely resected low grade gliomas: Southwest Oncology Group Study. J Neurosurg, 78: 909-914.
12. KARIM ABMF, MAAT B, HATLEVOLI R, et al. (1996). A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European organization for research and treatment of cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys, 36: 549-556.
13. KARIM AB, AFRA D, CORNU P, et al. (2002). Randomized trial on the efficacy of radiotherapy for cerebral low-grade gliomas in adults: EORTC 22845 with the Medical Research Council Study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys, 52: 316-324.
14. KLEIN M, HEIMANS JJ, AARONSON, et al. (2002). Effect of radiotherapy and other treatment-related factors on mid-term to long term cognitive sequelae in low-grade gliomas: a comparative study. Lancet, 360: 1361-1368.
15. LAWS ER, TAYLOR, WF, CLIFTON MB, et al. (1984). Neurosurgical management of low grade astrocytoma of the cerebral hemispheres. J Neurosurg, 61: 665-673.
16. LO SS, CHO KH, HERNANDEZ WL, Kossow RJ, LEE CK, CLARK HB. (2001). Does the extent of surgery have an impact on the survival of patients who receive postoperative radiation therapy for supratentorial low-grade gliomas? Int J Cancer, 96: 71-78.
17. MAC DONALD DR. (1994). Low grade gliomas, mixed gliomas and oligodendrogliomas. Semin Oncol, 2: 236-248.
18. MASSIMO M, SPREATICO F, CEFALO G, et al. (2002). High response rate to CDDP-etoposide regimen in chilhood low grade gliomas. J Clin Oncol, 21: 236-248.
19. NAKAMURA M, KONISHI N, TSUNODA S, et al. (2000). Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology, 58: 108-116.
20. OLSON JD, RIEDEL E, DE ANGELIS L. (2000). Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology, 54: 1442-1448.
21. PIGNATTI F, VAN DEN BENT M, CURRAN D, et al. (2002). Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol, 20: 2076-2084.
22. QUINN JA, REARDON DA, FRIEDMAN AH, et al. (2003). Phase II trial of temozolomide in patients with progressive low-grade gliomas. J Clin Oncol, 21: 646-651.
23. RECHT LD, LEW R, SMITH TW. (1992). Suspected low-grade glioma: is deferring treatment safe? Ann Neurol, 31: 431-6.
24. SCERRATI M, ROSELLI R, IACOANGELI M, POMPUCCI A, ROSSI F. (1996). Prognostic factors in low grade (WHO II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psy, 61: 291-296.
25. SCOTT JN, BRASHER PMA, SEVICK RJ, REWCASTLE NB, FORSYTH PA. (2002). How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology, 59: 947-949.
26. SHAW EG, DAUMAS-DUPORT C, SCHEITHAUER BW, et al. (1989). Radiation therapy in the management of low-grade supratentorial astrocytoma. J Neurosurg, 70: 853-861.
27. SHAW EG, ARUSELL R, SCHEITHAUER B, et al. (2002). A prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a NCCTG-RTOG-ECOG study. J Clin Oncol, 20: 2267-2276.
28. STREFFER J, SCHABET M, BAMBERT M, et al. (2000). A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol, 247: 297-302.
29. SURMA-AHO O, NIEMELA M, VILKKI J et al. (2001). Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology, 56: 1285-1290.
30. VAN DEN BENT MJ, KEIME-GUIBERT F, BRANDES AA, TAPHOORN MJB, KROS JM, ESKENS FALM, CARPENTIER AF. (2001). Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology; 57: 340-342.
31. VAN DEN BENT MJ, TAPHOORN MJB, BRANDES AA, et al. (2003). Phase II study of first line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the EORTC BTGS 26971. J Clin Oncol, 21:2525-2528.
32. VERTOSICK FIJR, SELKER RG, ARENA VC. (1991). Survival of patients with well-differentiated astrocytomas diagnosed in the era of chemotherapy. Neurosurgery, 28: 496-501.
33. WORLD HEALTH ORGANIZATION. (2000). Tumors of the nervous system, Pathology and genetic classification of tumors. Kleihues P, Cavenee WK editors. IARC Press, Lyon.